Low affinity TCRs targeting TAAs have produced limited anti-tumor function and proliferation in CD8+ T cells, and lack capability to redirect CD4+ T cells to MHC class I-restricted epitopes [59,60,61,62], which requires higher TCR affinities than most naturally occurring TCRs [62,63,64,65]. The gene discussed is CD8A; the disease is neoplasm.